Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicole Wong

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
The British Journal of Nutrition|May 13, 2026
Diet and risk of multiple myeloma: findings from a case-control studySimon Cheah, Allison M Hodge, Julie K Bassett, et al.
Disease Models & Mechanisms|September 29, 2020
A novel mouse model of Duchenne muscular dystrophy carrying a multi-exonic <i>Dmd</i> deletion exhibits progressive muscular dystrophy and early-onset cardiomyopathyTatianna Wai Ying Wong, Abdalla Ahmed, Grace Yang, et al.
Cancers|July 5, 2019
The Use of Optimal Treatment for DLBCL Is Improving in All Age Groups and Is a Key Factor in Overall Survival, but Non-Clinical Factors Influence TreatmentNicole Wong Doo, Victoria M White, Kara Martin, et al.
BMC Cancer|August 31, 2018
Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumoursNicola J Lawrence, Howard Chan, Guy Toner, et al.
Nature Genetics|September 14, 2004
A specific requirement for PDGF-C in palate formation and PDGFR-alpha signalingHao Ding, Xiaoli Wu, Hans Boström, et al.
European Journal of Haematology|July 3, 2024
A single-day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapiesEric Wenlong Li, Esther Jones, Christian Bryant, et al.
Nature Chemical Biology|August 21, 2025
Site-selective protein editing by backbone extension acyl rearrangementsLeah T Roe, Isabel M Piper, Carly K Schissel, et al.
British Journal of Cancer|February 12, 2016
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trialNiall C Tebbutt, Timothy J Price, Danielle A Ferraro, et al.
Cancer Epidemiology|May 16, 2025
Allergic disease and risk of multiple myeloma: A case-control studySimon Cheah, Adrian J Lowe, Nina Afshar, et al.
Asia-Pacific Journal of Clinical Oncology|March 23, 2026
Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant-Ineligible Newly Diagnosed Myeloma: An Australian Real-World, Multicenter StudySamantha Kurniawan, Angela Hwang, Nicole Wong Doo, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
The British Journal of Nutrition|May 13, 2026
Diet and risk of multiple myeloma: findings from a case-control studySimon Cheah, Allison M Hodge, Julie K Bassett, et al.
Disease Models & Mechanisms|September 29, 2020
A novel mouse model of Duchenne muscular dystrophy carrying a multi-exonic <i>Dmd</i> deletion exhibits progressive muscular dystrophy and early-onset cardiomyopathyTatianna Wai Ying Wong, Abdalla Ahmed, Grace Yang, et al.
Cancers|July 5, 2019
The Use of Optimal Treatment for DLBCL Is Improving in All Age Groups and Is a Key Factor in Overall Survival, but Non-Clinical Factors Influence TreatmentNicole Wong Doo, Victoria M White, Kara Martin, et al.
BMC Cancer|August 31, 2018
Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumoursNicola J Lawrence, Howard Chan, Guy Toner, et al.
Nature Genetics|September 14, 2004
A specific requirement for PDGF-C in palate formation and PDGFR-alpha signalingHao Ding, Xiaoli Wu, Hans Boström, et al.
European Journal of Haematology|July 3, 2024
A single-day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapiesEric Wenlong Li, Esther Jones, Christian Bryant, et al.
Nature Chemical Biology|August 21, 2025
Site-selective protein editing by backbone extension acyl rearrangementsLeah T Roe, Isabel M Piper, Carly K Schissel, et al.
British Journal of Cancer|February 12, 2016
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trialNiall C Tebbutt, Timothy J Price, Danielle A Ferraro, et al.
Cancer Epidemiology|May 16, 2025
Allergic disease and risk of multiple myeloma: A case-control studySimon Cheah, Adrian J Lowe, Nina Afshar, et al.
Asia-Pacific Journal of Clinical Oncology|March 23, 2026
Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant-Ineligible Newly Diagnosed Myeloma: An Australian Real-World, Multicenter StudySamantha Kurniawan, Angela Hwang, Nicole Wong Doo, et al.
Pageof 8